Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.

ABSTRACT:

Background

Upon treatment with biopharmaceuticals, the immune system may produce anti-drug antibodies (ADA) that inhibit the therapy. Up to 40% of multiple sclerosis patients treated with interferon β (IFNβ) develop ADA, for which a genetic predisposition exists. Here, we present a genome-wide association study on ADA and predict the occurrence of antibodies in multiple sclerosis patients treated with different interferon β preparations.

Methods

We analyzed a large sample of 2757 genotyped and imputed patients from two cohorts (Sweden and Germany), split between a discovery and a replication dataset. Binding ADA (bADA) levels were measured by capture-ELISA, neutralizing ADA (nADA) titers using a bioassay. Genome-wide association analyses were conducted stratified by cohort a

SUBMITTER: Andlauer TFM 

PROVIDER: S-EPMC7641861 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature